Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
AMES, Iowa , April 25, 2013 /PRNewswire/ --  NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that Nicholas N.
View HTML
Toggle Summary NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting
Results Support Further Evaluation of NLG919 for the treatment of Immunosupression Associated with Cancers
View HTML
Toggle Summary NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
AMES, Iowa , April 4, 2013 /PRNewswire/ --  NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics. The company today announced that preclinical data on one of its IDO pathway inhibitors, NLG919 , will be
View HTML
Toggle Summary NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
Clinical Trial Designed to Evaluate Novel IDO Pathway Inhibitor in Combination with Docetaxel
View HTML
Toggle Summary NewLink Genetics Reports Fourth Quarter and Full-Year 2012 Financial Results
Conference Call Scheduled for February 28, 2013
View HTML
Toggle Summary NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
AMES, Iowa , Feb. 25, 2013 /PRNewswire/ --  NewLink Genetics Corporation (Nasdaq:NLNK) today announced that its Fourth Quarter and fiscal year ended December 31, 2012 financial results will be released before the market opens on Thursday, February 28 , 2013.  The NewLink management team will host a
View HTML
Toggle Summary NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock
AMES, Iowa , Feb. 4, 2013 /PRNewswire/ --  NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently announced public offering of 4,000,000 shares of
View HTML
Toggle Summary NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
AMES, Iowa , Jan. 30, 2013 /PRNewswire/ --  NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at
View HTML
Toggle Summary NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
AMES, Iowa , Jan. 29, 2013 /PRNewswire/ --  NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public
View HTML
Toggle Summary NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development
Mr. Wiley Also to Direct Commercialization Strategy and Activities for algenpantucel-L
View HTML